Organic Active Ingredients TRIZ Cases

Segmented coating layers resolve low intestinal drug concentration by enabling precise colon targeting and reducing systemic toxicity.

A pharmaceutical composition combining biguanide derivatives with branched-chain amino acids to treat diabetes mellitus.

C21-substituted neuroactive steroids modulate brain excitability to treat inconsistent PMS and epilepsy outcomes.

Liposomal encapsulation improves oral bioavailability of Withaferin A, treating osteoporosis without invasive injections.

A free fatty acid extract formulation destroys viruses in the upper respiratory tract to reduce viral load by 90% to 99.99%.

Tryptase inhibitors and mast cell stabilizers suppress retinal neovascularization, resolving low prophylaxis effectiveness from non-specific treatments.

Indole derivatives antagonize glucagon receptors to reduce hepatic glucose output and enhance GLP-1 levels for improved glycemic control.

Sulfated polysaccharides coat PLGA nanoparticles to impart stable negative surface charge for enhanced cellular targeting.

Granulated magnesium lactate tablets resolve compressibility limits by achieving sustained mineral release through matrix erosion and diffusion mechanisms.

Compounds of formula (I) modulate GPR65 to inhibit tumour-permissive macrophage polarization and pathogenic Th17 differentiation in autoimmune disease.

Bispecific antibodies bind human VEGF and DLL4 to reduce tumor growth and cancer stem cell frequency while limiting side effects.

Combining USP7 and CD340 inhibitors overcomes trastuzumab resistance in refractory HER2-positive breast cancer models.

Inhaled ciclesonide prodrug converts to active metabolite in equine airways, reducing cortisol suppression and immune system alterations.

S1P receptor modulators reduce alcohol and drug intake by suppressing cravings, addressing limited therapeutic options for substance use disorders.

Modifying benzimidazole structures with fluorinated chains to enhance solubility and activity against respiratory syncytial virus.

Formula I tetracyclic heterocycles target the HCV NS5B polymerase enzyme, resolving insufficient antiviral activity by blocking RNA synthesis.

A benzodiazepine compound inhibits small cell lung cancer growth and induces cell death.

Oil-free wound composition eliminates lipid hindrance while maintaining therapeutic efficacy via water-soluble carriers.

Angular tricyclic compounds inhibit G9a and GLP enzymes to treat cancers and hemoglobinopathies.

A nasal rifampicin formulation enables direct brain transfer via the olfactory pathway.

Formulas I-XI inhibit apoptotic pathways and oxidative stress to prevent pancreatic beta cell degeneration in type I diabetes models.

Polyethylene oxide conjugates reduce metabolic degradation and improve aqueous solubility of small molecule protease inhibitors.

Indigestible fiber and lactic acid bacteria normalize dysbiotic gut microbiota in amino acid formula fed infants.

Low molecular weight heparin with reduced anticoagulant activity promotes hair growth to address chemotherapy-induced alopecia.

Segmenting the drug into a silicone vaginal ring reduces administration frequency while maintaining contraceptive efficacy.

AbCID systems use human-derived antibodies to create molecular switches that regulate cellular therapies with high precision.

Lowering microcrystalline cellulose while adding mannitol accelerates AZD9291 dissolution, reducing pH-dependent absorption variability.

Nitrogen-filled laminated sachets maintain ethanol concentration and prevent contamination in liquid T3 and T4 formulations.

Measuring baseline CD14+CD16+ concentrations selects patients for 2-arylbenzimidazole therapy, bypassing difficult CNS inflammation assessment.

Calcimycin blocks Prp8 intein splicing to overcome drug resistance and limited permeability in cryptococcal infections.

Chromatography and spectral analysis quantify trace carbamate impurities to maintain pharmaceutical purity standards.

5-membered heteroaryl carboxamide compounds disrupt HBV core protein assembly to treat Hepatitis B infections.

Hydrophobic cellulose minimizes electrostatic attraction to reduce airborne dusting, enabling accurate delivery of hydrophilic starch for skin benefits.

L-ergothioneine eyedrops scavenge reactive oxygen species to prevent hyaluronan depolymerization and vitreous liquefaction.

Small molecule inhibitors cross the blood-brain barrier to treat neurological lysosomal storage disorders.

Single-layer balloon coating uses controlled limus drug crystallinity to enable rapid initial release and sustained bioavailability.

A fisetin production method uses recrystallization to purify derivatives without column chromatography.

A micronutrient composition enhances extracellular matrix component deposition by synovial cells.

Formula I compounds modulate histone acetyltransferase activity to treat neurodegenerative disorders and cancer.

One-pot hydrolysis and precipitation eliminate intermediate isolation steps, boosting yield and reducing waste.

Removing preservatives from the treprostinil sodium composition eliminates local tissue pain while maintaining isotonicity and stability.

Urea complexation removes saturated fats from ethyl ester mixtures, achieving 90% purity.

GABA receptor agonists mediate immune interactions to restore pancreatic function, reducing lifelong insulin burden.

Continuous infusion of lenalidomide eliminates peak-valley fluctuations, reducing neutropenia while maintaining therapeutic efficacy.

Sustained release carriers stabilize drug concentration to prevent muscle toxicity while maintaining lipid-lowering efficacy.

Specific chemical structures target anti-apoptotic Bcl-2 proteins, resolving chemotherapy resistance and improving clinical efficacy.